Transaction · 0001931382-26-000007

Gc Corp.

GC Corp., 10%, reported an open-market or private purchase at Artiva Biotherapeutics, Inc. involving 347222.000000 shares for an estimated $3999997.44. Reported holdings after the transaction were 1607734.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market buySEC transaction code P10%
ARTVArtiva Biotherapeutics, Inc.
Trade date
May 11, 2026
Filing date
May 28, 2026
View on SEC Insider profile
Disclosed value$3.99MShares × reported price
Shares traded347k$11.52 per share
Holdings after1.60MIndirect · By GC Cell Corporation
% of reported position traded27.55%This security and ownership context
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 1,260,512 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Filing warnings

Notes recorded with this filing
1 warning
delayed filingThe filing was reported 17 calendar days after the transaction date.

ARTV price since this filing

Daily closing prices, with the filing date and available return windows
ARTV · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -10.5%1w ago +48.4%1d ago +43.1%
Returns since7d +0.9%30d +26.4%90d +54.7%180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Buy
Code P
Identifier
0001931382-26-000007
Common Stock
Transaction date
May 11, 2026
Filed May 28, 2026, 08:34 PM · 17d delay
Shares
347,222 sh
$11.52 per share
Estimated value
$3.99M
Computed from shares × price
Holdings after
1,607,734 sh
Indirect · By GC Cell Corporation

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Buy Delayed Filing Large Buy Repeat Buyer 10% Owner Buy
Filing-only score

+42 points

Compact filing score computed from stored Form 4 facts. Version v1.

Strong filing signal

This filing has a high positive filing-only score. It may deserve closer research, but it is not an investment recommendation.

How this score is calculated
  • open_market_purchase+12 points

    transaction_code = P

    Code P is a discretionary open-market purchase.
  • ten_percent_owner_buy+4 points

    is_ten_percent_owner = true

    10% beneficial owner open-market purchase.
  • cluster_buy+14 points

    cluster-buy signal matched

    Multiple insiders bought within the configured window.
  • repeat_buyer+8 points

    repeat-buyer signal matched

    Same insider bought again within the configured window.
  • large_buy_absolute+10 points

    large-buy signal with absolute_triggered = true

    Open-market purchase exceeds the configured absolute threshold.
  • delayed_filing-6 points

    reporting_delay_days = 17

    Filing delay exceeds the configured threshold.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

No officer title

Officer NoDirector No10% YesOther No
Footnotes & amended
  1. F1

    GC Corp., a public Korean holdings company, is ultimately controlled by its board of directors. As of March 26, 2026, the board consists of: Mr. Yong-Jun Huh, Huh Il-Sup, Park Yong-Tae, Kang Joonho, a…

  2. F2

    The shares are held directly by GC Cell Corporation. GC Corp., a public Korean holdings company, is the parent company of GC Cell Corporation and is ultimately controlled by its board of directors. As…

Original filing · 0001931382-26-000007
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

ARTV